US2016326487A1PendingUtilityA1

Stem Cells Derived from Pure Chorionic Trophoblast Layer and Cell Therapy Comprising Same

Assignee: SAMSUNG LIFE PUBLIC WELFARE FOUNDATIONPriority: Jan 8, 2014Filed: Jan 8, 2015Published: Nov 10, 2016
Est. expiryJan 8, 2034(~7.5 yrs left)· nominal 20-yr term from priority
A61P 19/08A61P 19/04A61P 25/00A61P 19/02A61P 19/00A61K 35/50C12N 2506/1392A61K 35/12C12N 5/0605C12N 5/0654C12N 5/0668C12N 2506/03C12N 5/0606C12N 5/0655C12N 2506/025C12N 5/0653C12N 5/066C12N 5/0619
38
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure relates to stem cells derived from a pure chorionic trophoblast layer (chorionic trophoblast layer without villi, CT-V), which is a part of the tissues of the placenta, and cell therapy comprising same. Stem cells derived from a pure chorionic trophoblast layer according to the present invention exhibit uniform growth characteristic, and superb proliferation and differentiation characteristics compared to the conventional stem cells derived from the whole placenta, and particularly, exhibit excellent differentiation into cartilage cells, thus can be effectively used in cell therapy for treating cartilage damage, deficiency and such, and as a composition for tissue regeneration.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . Stem cells derived from a pure chorionic trophoblast layer (a chorionic trophoblast layer without villi, CT-V) which is a part of the tissues of the placenta. 
     
     
         2 . The stem cells of  claim 1 , wherein the stem cells are positive for surface markers CD44, CD73, CD90, and CD105. 
     
     
         3 . The stem cells of  claim 1 , wherein the stem cells are negative for surface markers CD31, CD34, CD45, and HLA-DR. 
     
     
         4 . The stem cells of any one of  claims 1  to  3 , wherein the stem cells derived from the pure chorionic trophoblast layer are derived from a tissue which is removed chorionic villi of the chorionic trophoblast layer positioned between a chorionic membrane and a decidua. 
     
     
         5 . The stem cells of any one of  claims 1  to  3 , wherein the stem cells are prepared by the following steps:
 (a) isolating a pure chorionic trophoblast layer (chorionic trophoblast layer without villi, CT-V), which is a part of the tissues of the placenta, from placenta; 
 (b) obtaining cells derived from the pure chorionic trophoblast layer by treating one or more kinds of enzymes selected from the group consisting of trypsin, collagenase, dispase, DNase, RNase, protease, lipase, hyaluronidase, and elastase to the isolated pure chorionic trophoblast layer tissue; and 
 (c) screening the stem cells from the obtained cells derived from the pure chorionic trophoblast layer. 
 
     
     
         6 . A cellular therapeutic agent comprising stem cells derived from a pure chorionic trophoblast layer (chorionic trophoblast layer without villi, CT-V) which is a part of the tissues of the placenta; or cells differentiated from the stem cells as an active ingredient. 
     
     
         7 . The cellular therapeutic agent of  claim 6 , wherein the cells differentiated from the stem cells are one or more kinds selected from the group consisting of chondrogenic, adipogenic, osteogenic, neuron, ligament, and tenocyte. 
     
     
         8 . The cellular therapeutic agent of  claim 6  or  7 , wherein the cellular therapeutic agent is used for treating cartilage damage, cartilage defect, bone defect, tendon-ligament defect, or fat tissue defect. 
     
     
         9 . The cellular therapeutic agent of  claim 8 , wherein the cartilage defect is one or more kinds selected from the group consisting of cartilage injury, cartilage tear, chondromalacia, cartilage necrosis, osteochondritis, cartilage loss, and osteoarthritis. 
     
     
         10 . A composition for regenerating tissues comprising stem cells derived from a pure chorionic trophoblast layer (chorionic trophoblast layer without villi, CT-V) which is a part of the tissues of the placenta; or cells differentiated from the stem cells as an active ingredient. 
     
     
         11 . The composition of  claim 10 , wherein the tissue is one or more kinds selected from the group consisting of cartilage, fat, bone, nerve, ligament, and tendon. 
     
     
         12 . The composition of  claim 11 , wherein the cartilage is hyaline cartilage, fibrocartilage, or elastic cartilage. 
     
     
         13 . The composition of  claim 11 , wherein the cartilage is one or more kinds selected from the group consisting of articular cartilage, ear cartilage, nasal cartilage, elbow cartilage, meniscus, knee cartilage, costal cartilage, ankle cartilage, tracheal cartilage, laryngeal cartilage, and spinal cartilage.

Join the waitlist — get patent alerts

Track US2016326487A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.